Small-molecule PDE4 inhibitors, which forestall cAMP degradation, have showcased efficacy across a myriad of inflammatory conditions, encompassing Inflammatory Bowel Disease, Atopic Dermatitis, and Rheumatoid Arthritis [55, 56]. Here, PDE4A is linked to inflammatory bowel disease.